Literature DB >> 1387511

Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.

A B Cohen1, M D Stevens, E J Miller, M A Atkinson, G Mullenbach.   

Abstract

The neutrophil-activating peptide-2 (NAP-2) is a cytokine that is generated by the proteolytic cleavage of a precursor protein and that causes neutrophil degranulation and chemotaxis. NAP-2 precursors are produced in platelets and are normally found in the circulation. We showed that NAP-2 is generated by the action of neutrophil cathepsin G on two of the precursors, the connective tissue-activating peptide-III (CTAP-III) and beta-thromboglobulin (beta-TG). However, neutrophil elastase degraded the precursors to inactive peptides. The specific binding of cathepsin G to platelets caused the platelets to secrete NAP-2, and cathepsin G bound to the platelets could still generate NAP-2 from its precursor proteins. In addition, activated neutrophils in the presence of platelets generated NAP-2 from its precursors and caused platelets to secrete NAP-2. These studies demonstrate a unique mechanism for the activation of neutrophils through the interaction of neutrophils, platelets, and NAP-2 precursors that are released either by activated platelets or are present in circulation. It is therefore possible that NAP-2 may be generated at sites where aggregations of neutrophils and platelets occur in vessels such as pulmonary capillaries in patients with the adult respiratory distress syndrome and coronary arteries in patients with evolving myocardial infarctions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387511     DOI: 10.1152/ajplung.1992.263.2.L249

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

Review 3.  Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.

Authors:  A Del Maschio; E Dejana; G Bazzoni
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

4.  Biologically active neutrophil chemokine pattern in tonsillitis.

Authors:  C Rudack; S Jörg; F Sachse
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

5.  Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties.

Authors:  M Detheux; L Ständker; J Vakili; J Münch; U Forssmann; K Adermann; S Pöhlmann; G Vassart; F Kirchhoff; M Parmentier; W G Forssmann
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

6.  Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction.

Authors:  James R Wodicka; Andrea M Chambers; Gurneet S Sangha; Craig J Goergen; Alyssa Panitch
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-29

7.  Mapping of type 2 diabetes proteins to COVID-19 biomarkers: A proteomic analysis.

Authors:  Abu Saleh Md Moin; Ahmed Al-Qaissi; Thozhukat Sathyapalan; Stephen L Atkin; Alexandra E Butler
Journal:  Metabol Open       Date:  2020-12-13

Review 8.  Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation.

Authors:  Jonathan Mandel; Martina Casari; Maria Stepanyan; Alexey Martyanov; Carsten Deppermann
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.